<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04832776</url>
  </required_header>
  <id_info>
    <org_study_id>Cetu-Bev-FOLFOXIRI</org_study_id>
    <nct_id>NCT04832776</nct_id>
  </id_info>
  <brief_title>FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases</brief_title>
  <official_title>FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the&#xD;
      conversion therapy of right-sided colon cancer liver metastases&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 17, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>objective response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate of liver metastases</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>R0 resection rate of liver metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NED rate</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>percentage of patients who reach NED</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 6 months</time_frame>
    <description>overal survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>progression free survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Liver Metastasis Colon Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOXIRI+C225</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOXIRI+BEV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>one group plus cetuximab</description>
    <arm_group_label>FOLFOXIRI+C225</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>one group plus bevacizumab</description>
    <arm_group_label>FOLFOXIRI+BEV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOXIRI</intervention_name>
    <description>FOLFOXIRI</description>
    <arm_group_label>FOLFOXIRI+BEV</arm_group_label>
    <arm_group_label>FOLFOXIRI+C225</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG perfomance 0-1&#xD;
&#xD;
          -  pathologically confirmed colorectal carcinoma, with RAS wild type&#xD;
&#xD;
          -  inital unresectable liver metastases discussed by MDT&#xD;
&#xD;
          -  prior no systemical therapy or exceed 6 months after the adjuvant chemotherapy of&#xD;
             primary tumor surgery.&#xD;
&#xD;
          -  without extraheptic metastatic lesions, except for locally controlled lung metastases&#xD;
             (RFA or SBRT)&#xD;
&#xD;
          -  adequate blood, liver and renal function&#xD;
&#xD;
          -  expected survival longer than 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  with bleeding risk&#xD;
&#xD;
          -  interestinal obstruction or disease&#xD;
&#xD;
          -  uncontrolled hypertension and severe heart disease&#xD;
&#xD;
          -  previous severe thrombotic events&#xD;
&#xD;
          -  central nervous system metastases&#xD;
&#xD;
          -  accompanied with other malignant tumor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenhua Li</last_name>
    <phone>13817922257</phone>
    <phone_ext>13817922257</phone_ext>
    <email>whliiris@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Colorectal Surgery Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjun Cai, M.D</last_name>
      <phone>+86-21-64175590</phone>
      <phone_ext>81108</phone_ext>
      <email>caisanjuncsj@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Sanjun Cai</investigator_full_name>
    <investigator_title>Department of Colorectal Surgery</investigator_title>
  </responsible_party>
  <keyword>FOLFOXIRI</keyword>
  <keyword>cetuximab</keyword>
  <keyword>bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

